These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 24706671)

  • 1. Enzalutamide shows strong activity in prostate cancer.
    Cancer Discov; 2014 Apr; 4(4):OF2. PubMed ID: 24706671
    [No Abstract]   [Full Text] [Related]  

  • 2. Enzalutamide for the treatment of metastatic castration-resistant prostate cancer.
    Rodriguez-Vida A; Galazi M; Rudman S; Chowdhury S; Sternberg CN
    Drug Des Devel Ther; 2015; 9():3325-39. PubMed ID: 26170619
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enzalutamide and metastasis risk in prostate cancer.
    Gourd E
    Lancet Oncol; 2018 Aug; 19(8):e387. PubMed ID: 29983344
    [No Abstract]   [Full Text] [Related]  

  • 4. Enzalutamide versus flutamide for castration-resistant prostate cancer after combined androgen blockade therapy with bicalutamide: study protocol for a multicenter randomized phase II trial (the OCUU-CRPC study).
    Iguchi T; Tamada S; Kato M; Yasuda S; Yamasaki T; Nakatani T
    BMC Cancer; 2019 Apr; 19(1):339. PubMed ID: 30971225
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enzalutamide versus flutamide for castration-resistant prostate cancer after combined androgen blockade therapy with bicalutamide: a retrospective study.
    Iguchi T; Tamada S; Kato M; Yasuda S; Otoshi T; Hamada K; Yamasaki T; Nakatani T
    Int J Clin Oncol; 2019 Jul; 24(7):848-856. PubMed ID: 30741370
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapies for castration-resistant prostate cancer in a new era: The indication of vintage hormonal therapy, chemotherapy and the new medicines.
    Mizokami A; Kadono Y; Kitagawa Y; Izumi K; Konaka H
    Int J Urol; 2017 Aug; 24(8):566-572. PubMed ID: 28577511
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Do we need new trials for the abiraterone, enzalutamide and cabazitaxel in metastatic castrate-resistant prostate cancer for confirmation of treatment indications?
    Arslan C
    World J Urol; 2017 Mar; 35(3):479-480. PubMed ID: 27417948
    [No Abstract]   [Full Text] [Related]  

  • 8. Fatigue, quality of life and metabolic changes in men treated with first-line enzalutamide versus abiraterone plus prednisolone for metastatic castration-resistant prostate cancer (HEAT): a randomised trial protocol.
    Kvorning Ternov K; Sønksen J; Fode M; Lindberg H; Kistorp CM; Bisbjerg R; Palapattu G; Østergren PB
    BMJ Open; 2019 Sep; 9(9):e030218. PubMed ID: 31511288
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enzalutamide before chemotherapy prolongs survival.
    Cancer Discov; 2014 Jul; 4(7):OF5. PubMed ID: 25002634
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Enzalutamide-new option in metastatic castration-sensitive prostate cancer? : Preliminary results of a randomized phase III trial (ENZAMET)].
    Boegemann M
    Urologe A; 2020 Jan; 59(1):78-79. PubMed ID: 31853892
    [No Abstract]   [Full Text] [Related]  

  • 11. [Prostate cancer - enzalutamide extends survival].
    Aktuelle Urol; 2014 Mar; 45(2):98. PubMed ID: 24818263
    [No Abstract]   [Full Text] [Related]  

  • 12. New Hormonal Agents in Patients with Nonmetastatic Castration-resistant Prostate Cancer: Can We Be Satisfied with an Advantage in Metastasis-free Survival?
    Di Nunno V; Santoni M; Massari F
    Eur Urol Oncol; 2019 Jul; 2(4):471. PubMed ID: 31277785
    [No Abstract]   [Full Text] [Related]  

  • 13. Long-term Efficacy and Safety Results: Can Enzalutamide Challenge the Dogma of Androgen Deprivation Therapy in Hormone-naïve Prostate Cancer?
    Albiges L; Loriot Y; Massard C; Fizazi K
    Eur Urol; 2015 Nov; 68(5):802-4. PubMed ID: 25922192
    [No Abstract]   [Full Text] [Related]  

  • 14. Is in vitro-acquired resistance to enzalutamide a useful model?
    Buonerba C; Di Lorenzo G
    Future Oncol; 2014 Dec; 10(16):2551-3. PubMed ID: 25531044
    [No Abstract]   [Full Text] [Related]  

  • 15. The evolving role of enzalutamide on the treatment of prostate cancer.
    Nadal R; Bellmunt J
    Future Oncol; 2016 Mar; 12(5):607-16. PubMed ID: 26839021
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential Side Effects Profile in mCRPC Patients Treated With Abiraterone or Enzalutamide: A Meta-Analysis of Randomized Controlled Trials.
    Clin Adv Hematol Oncol; 2016 Apr; 14(4 Suppl 5):14-5. PubMed ID: 27167845
    [No Abstract]   [Full Text] [Related]  

  • 17. [Advances in the treatment of castration-resistant prostate cancer: emphasis in new hormonal therapies].
    Berlin A; Fernández MI
    Rev Med Chil; 2015 Feb; 143(2):223-36. PubMed ID: 25860365
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and effectiveness of enzalutamide in men with metastatic, castration-resistant prostate cancer.
    Graff JN; Gordon MJ; Beer TM
    Expert Opin Pharmacother; 2015 Apr; 16(5):749-54. PubMed ID: 25687355
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Flutamide as an Alternative Anti-androgen Agent and Predictor of the Efficacy of Novel Androgen Receptor-targeted Agents.
    Yamaguchi N; Morizane S; Yumioka T; Iwamoto H; Hikita K; Sejima T; Honda M; Takenaka A
    Anticancer Res; 2019 Jul; 39(7):3879-3885. PubMed ID: 31262916
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The clinical benefit of sequential therapy with androgen receptor axis-targeted agents alone in patients with castration-resistant prostate cancer: A propensity score-matched comparison study.
    Naito Y; Kato M; Kawanishi H; Yuguchi Y; Yuba T; Ishikawa T; Hattori K; Yamamoto A; Sano T; Matsukawa Y; Kimura T; Nishikimi T; Hattori R; Tsuzuki T; Gotoh M
    Prostate; 2020 Nov; 80(15):1373-1380. PubMed ID: 32914895
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.